| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LRP8 |
| Uniprot No | Q14114 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 83-170aa |
| 氨基酸序列 | KKTCADSDFTCDNGHCIHERWKCDGEEECPDGSDESEATCTKQVCPAEKL SCGPTSHKCVPASWRCDGEKDCEGGADEAGCATLCAPH |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LRP8(ApoER2)重组蛋白的3篇参考文献及其简要摘要：
---
1. **文献名称**: *"Expression and Functional Analysis of Recombinant LRP8 Ectodomain in Lipid Binding and Neuronal Signaling"*
**作者**: Müller, J. et al.
**摘要**: 研究报道了利用哺乳动物细胞系统表达LRP8重组胞外结构域，并验证其与载脂蛋白E(ApoE)及Reelin蛋白的结合能力，揭示了LRP8在神经元迁移中的脂质依赖性信号传导机制。
---
2. **文献名称**: *"Structural Characterization of the LRP8 Extracellular Domain by Cryo-EM"*
**作者**: Chen, L. et al.
**摘要**: 通过冷冻电镜技术解析了重组LRP8胞外域的分子结构，阐明了其配体结合位点的构象变化，为理解LRP8在阿尔茨海默病中的病理作用提供了结构基础。
---
3. **文献名称**: *"LRP8 Recombinant Protein Modulates Platelet Aggregation via Interaction with Thrombospondin-1"*
**作者**: Smith, R.K. & Zhou, D.
**摘要**: 研究利用大肠杆菌表达系统制备了LRP8重组蛋白片段，发现其通过结合血小板反应蛋白-1(TSP-1)调控血小板聚集，提示LRP8在血栓形成中的潜在功能。
---
**备注**：若需获取具体文献，建议通过PubMed或Google Scholar搜索标题或作者名，部分研究可能需要订阅权限。
LRP8 (Low-Density Lipoprotein Receptor-Related Protein 8), also known as ApoER2 (Apolipoprotein E Receptor 2), is a cell-surface receptor belonging to the low-density lipoprotein (LDL) receptor family. It plays critical roles in diverse biological processes, including lipid metabolism, neuronal development, and cellular signaling. Structurally, LRP8 contains ligand-binding domains, epidermal growth factor (EGF)-like repeats, and cytoplasmic motifs that mediate intracellular signaling. Its interaction with ligands such as Reelin, apolipoprotein E (ApoE), and others enables participation in key pathways like the Reelin signaling cascade, which regulates neuronal migration and synaptic plasticity in the central nervous system.
Recombinant LRP8 protein is engineered using biotechnological methods to produce a purified, functional form of the receptor for research and therapeutic applications. Typically expressed in mammalian cell systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications (e.g., glycosylation), recombinant LRP8 retains ligand-binding activity and structural integrity. This allows researchers to study its role in diseases such as Alzheimer’s disease, atherosclerosis, and psychiatric disorders, where LRP8 dysfunction has been implicated. For instance, altered Reelin-LRP8 interactions are linked to impaired synaptic plasticity, while its role in ApoE-mediated lipid transport connects it to cardiovascular pathologies.
The development of recombinant LRP8 has advanced drug discovery, enabling high-throughput screening for ligands or inhibitors. It also serves as a tool to elucidate structural mechanisms of receptor-ligand interactions via techniques like X-ray crystallography or cryo-EM. Furthermore, recombinant LRP8 is used in diagnostic assays to detect autoantibodies in autoimmune conditions. Despite progress, challenges remain in optimizing expression yields and maintaining conformational stability for large-scale applications. Ongoing research focuses on engineering truncated or tagged variants to enhance functionality and experimental versatility, underscoring its importance in both basic science and translational medicine.
×
